[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,76,101,131,158,189,218],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100637201","phase-1-a-phase-i-trial-of-s-adenosylmethionine-same-for-chemoprevention-of-colorectal-adenomas-100637201",false,"NCT07582003","A Phase I Trial of S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas","Inclusion Criteria:\n\n1\\) Adults ≥18 years old with histologically confirmed, curatively resected stage I-II colorectal cancer; 2) must agree to pre-intervention (baseline) stool sample and distal colon biopsy; 3) must start study intervention within 30 days ±7 days of the baseline biopsy; 4) must be able to complete up to 12 months of intervention prior to planned postoperative surveillance colonoscopy within 1 year of surgery; 5) must undergo repeat stool sample and distal colon biopsy within 7 days ±4 days of the last dose of study intervention; 6) did not receive adjuvant therapy; 7) not currently breastfeeding or pregnant.\n\nExclusion Criteria:\n\n1\\) Have a history familial adenomatous polyposis (FAP); 2) have a history of hereditary nonpolyposis colorectal cancer; 3) history of inflammatory bowel disease; 4) high-dose aspirin (except for low-dose (≤100 mg\u002Fday) aspirin for cardiovascular prevention) within the past 60 days of enrollment.","ALL","18 Years",{"count":18,"type":19},18,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This study will enroll a total of 18 patients who have undergone curative surgery for stage I or II colorectal cancer and are planned for post-surgical surveillance without any need for chemotherapy at Cedars-Sinai Medical Center. All subjects will receive an oral daily supplement called S-Adenosylmethionine (SAMe) which has been hypothesized to reduce colorectal polyps (precursors to colorectal cancer) and prevent colorectal cancer formation. The study investigates what the appropriate dosage of SAMe is so that there is the lowest risk of side effects, and whether the supplement will prevent polyp formation in a population of patients who at risk for developing polyps and colorectal cancer. The primary endpoint will be to determine the recommended phase II dose (RP2D), the highest safe dose of SAMe that could be studied in larger clinical trials to advance this agent further in clinical development. Secondary endpoints include safety, the rate of postoperative adenomas detected on surveillance colonoscopy, and the effects of SAMe on the colon, specifically, its impact on gut bacteria and tissue markers before and after SAMe treatment to better understand the mechanisms to how SAMe may have its colorectal cancer preventive effects.",[25,26],"Colorectal Cancer (Diagnosis)","Adenoma",[26,28,29],"Colorectal Cancer","S-Adenosylmethionine (SAMe)","NOT_YET_RECRUITING","2026-05-06",{"date":33,"type":34},"2026-05-12","ACTUAL",{"date":36,"type":19},"2026-06-01",{"date":38,"type":19},"2028-06-01",{"name":40,"class":41},"Jun Gong, MD","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},"100616587","efficacy-of-ai-assisted-colonoscopy-for-screening-colorectal-neoplasia-ai-coloscreen-100616587","NCT07307547","Efficacy of AI-Assisted Colonoscopy for Screening Colorectal Neoplasia (AI-COLOSCREEN)","A Multi-center, Randomized, Controlled Clinical Study on the Efficacy of Artificial Intelligence-Assisted Colonoscopy in Improving the Screening of Colorectal Cancer and Precancerous Lesions.","AI-COLOSCREEN","Inclusion Criteria:\n\n1. Age between 18 and 75 years, inclusive.\n2. Scheduled for a screening, diagnostic, or surveillance colonoscopy.\n3. Able to understand the study protocol and provide written informed consent.\n\nExclusion Criteria:\n\n1. Known contraindications to colonoscopy or biopsy.\n2. Personal history of colorectal cancer, inflammatory bowel disease (IBD), or previous colorectal surgery.\n3. Known or suspected colorectal polyposis syndrome (e.g., Familial Adenomatous Polyposis - FAP).\n4. Patients with active colorectal bleeding, bowel obstruction, or toxic megacolon.\n5. Women who are pregnant, planning to become pregnant, or are breastfeeding.\n6. Participation in another interventional clinical trial within the 30 days prior to enrollment.\n7. Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.",true,"75 Years",{"count":54,"type":19},3342,[56],"NA","This study is a multi-center, randomized controlled trial designed to evaluate whether an artificial intelligence (AI) system can assist endoscopists to improve the detection rate of colorectal adenomas and cancers during colonoscopy compared to standard colonoscopy. Early screening and diagnosis are key to reducing the burden of colorectal cancer, but current colonoscopy has limitations, including the risk of missed lesions. This trial aims to determine if AI can enhance screening quality and diagnostic accuracy.",[59,60,26,28],"Colorectal Neoplasms","Colonic Polyp",[62,63,64,65,66],"Artificial Intelligence","Colonoscopy","Colorectal Cancer Screening","Adenoma Detection Rate","Deep Learning","2026-02-08",{"date":69,"type":34},"2026-02-10",{"date":71,"type":19},"2026-04",{"date":73,"type":19},"2028-12",{"name":75,"class":41},"Zhejiang University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":20,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":42},"100509387","evaluation-of-early-home-return-in-patients-with-enucleation-of-prostate-adenoma-100509387","NCT05912764","Evaluation of Early Home Return in Patients With Enucleation of Prostate Adenoma","Evaluation of Early Home Return Care Pathway in Patients Who Have Undergone Endoscopic Enucleation of Prostate Adenoma by Laser","PRECODOM","Inclusion Criteria:\n\n* Patient planned for endoscopic enucleation of prostate adenoma with laser\n* Patient with symptomatic benign prostatic hyperplasia and refractory to medical reatment and\u002For\n* Patient with benign prostatic hyperplasia complicated by chronic retention of urine and\u002For\n* Patient with benign prostatic hyperplasia complicated by prostatitis and\u002For\n* Patient with symptomatic benign prostatic hyperplasia\n\nExclusion Criteria:\n\n* Patient living beyond the scope of care by the nurses coordination\n* Bedridden patient or WHO clinical condition \\>2\n* Patient requiring curative anticoagulation which cannot be interrupted or relayed at home by heparin\n* Patient with double anti-platelet aggregation who cannot be interrupted","MALE","45 Years",{"count":87,"type":19},440,[56],"Prostate adenoma management includes, if necessary, surgical treatments: resection or vaporization by endoscopy or by open surgery in case of a very large prostate. Laser technology is a curative treatment for prostate adenoma. The minimum duration of hospitalization, in the context of enucleation prostatic endoscopy by laser, is estimated at 48 hours.\n\nThe Union Clinique has developed an improved rehabilitation care pathway reducing hospitalization duration to 24 hours (one night hospitalization). This care pathway involves patient as an actor in its care but also health professionals, in particular nurses.\n\nThis study is based on the hypothesis that the model developed by the Union Clinique can be translated to other healthcare establishments and that home return supervized by nurses allows reducing hospital stay length without increasing the risk of serious complications for patients",[26],"RECRUITING","2025-11-18",{"date":94,"type":34},"2025-11-24",{"date":96,"type":34},"2024-01-26",{"date":98,"type":19},"2027-08-15",{"name":100,"class":41},"GCS Ramsay Santé pour l'Enseignement et la Recherche",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":20,"phases":111,"briefSummary":112,"conditions":113,"keywords":119,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":42},"100546705","phase-1-r-5780-01-in-combination-with-pd-1-checkpoint-inhibitors-checkpoint-protein-on-immune-cells-called-t-cells-in-patients-with-solid-tumors-100546705","NCT06398418","R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors","A Single and Repeat Dosing and Expansion Study of the Safety, Drug Exposure and Clinical Activity of R-5780 in Combination With a PD-1 (Checkpoint Protein on Immune Cells Called T Cells) Pathway Checkpoint Inhibitor in Patients With Solid Tumors","Inclusion Criteria:\n\n* At least 18 years of age to 80\n* Ability to provide written informed consent\n* Unresectable stage III or stage IV melanoma, basal cell carcinoma, or squamous cell carcinoma as per the American Joint Committee on Cancer 2017 Guidelines (8th Edition) regardless of BRAF mutation status and other solid tumors.\n* Refractory to anti-PD (checkpoint Protein on Immune Cells called T cells)-1\u002FL1 therapy per RECIST v1.1 defined as subject who has disease progression after receiving at least two complete cycles of ICI (immune checkpoint inhibitors) therapy or disease progression 6 months from initiation of ICI (immune checkpoint inhibitors) therapy while still on active therapy.\n* Life expectancy of greater than 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n* Subjects must have evaluable disease by CT (computer tomography) or MRI (magnet resonance imaging) per RECIST 1.1 criteria or clinically apparent disease that the investigator can follow for response.\n\nExclusion Criteria:\n\n* Any serious medical condition or laboratory abnormality or psychiatric condition or any other significant or unstable concurrent medical illness (in the opinion of the Investigator) would preclude protocol adherence or would make the safety of the study drug difficult to assess\n* Treatment with systemic broad-spectrum antibiotics.\n* No active viral infections.\n* Coexisting severe chronic diseases other than cancer (autoimmunity, inflammatory diseases)\n* Secondary gastrointestinal motility disorders\n* History of solid organ transplant or bone marrow transplant\n* Prior CAR-T (chimeric antigen receptor) or allogeneic cellular therapy\n* Ongoing systemic immunosuppressive therapy, with the exclusion of prednisone (10 mg\u002Fday)\n* Concurrent therapy with any other investigational agent, vaccine, or device\n* Pregnant or breastfeeding or planning to conceive or father a child during the trial period\n* Subjects with untreated brain metastasis. Treated brain metastasis are permitted if stable\n* More than 4 prior systemic therapies\n* Other cancer medications during treatment period are not permitted\n* Enrollment in other clinical trials.","80 Years",{"count":110,"type":19},33,[22],"The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.",[114,115,116,117,118,26],"Solid Tumor, Adult","Solid Tumor","Melanoma","Basal Cell Cancer","Squamous Cell Cancer",[120],"Solid Tumors","2025-08-27",{"date":123,"type":34},"2025-09-04",{"date":125,"type":34},"2025-08-01",{"date":127,"type":19},"2027-12-31",{"name":129,"class":130},"Rise Therapeutics LLC","INDUSTRY",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":139,"studyType":140,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100603929","gastroduodenal-full-thickness-resection-device-registry---gdftrd-registry-100603929","NCT07142902","Gastroduodenal Full Thickness Resection Device Registry - gdFTRD® Registry","Inclusion criteria:\n\n* All patients of legal age in whom the gdFTRD was used for treatment in the upper GI tract (stomach and duodenum) independently from the registry and\n* who gave informed consent to data processing\n\nExclusion criteria:\n\n* Patients aged under 18 years\n* Patients in whom the colonic FTRD, diagnostic FTRD or non-device assisted EFTR was used for treatment\n* Patients who did not give informed consent to data processing",{"count":138,"type":19},306,"3 Years","OBSERVATIONAL","Endoscopic full-thickness resection (EFTR) is a therapeutic option for the treatment of challenging lesions such as subepithelial tumors (SETs) and epithelial neoplasia extending deeper than the mucosa or associated with significant fibrosis. EFTR may offer a less invasive treatment alternative relative to surgical approaches in selected patients.\n\nThe gastroduodenal FTRD System (gdFTRD System) is an instrument for endoscopic full-thickness resection or deep partial wall resection and diagnostic tissue acquisition through removal of suitable lesions in the stomach and duodenum.\n\nThe prospectively generated data of the gdFTRD registry shall be used to evaluate the application of the gdFTRD in clinical routine, to verify the acceptability of already known risks and to identify unknown risks and complications.",[143,26],"Subepithelial Gastrointestinal Tumors",[145,146,147,148],"gdFTRD","gastroduodenal full thickness resection","endoscopic full thickness resection","EFTR","2025-08-19",{"date":121,"type":34},{"date":152,"type":19},"2025-08",{"date":154,"type":19},"2030-08",{"name":156,"class":130},"Ovesco Endoscopy AG",3,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":164,"targetDuration":166,"studyType":140,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":157},"100412277","proton-therapy-research-infrastructure--protrait--neuro-oncology-100412277","NCT04648462","Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology","Inclusion Criteria:\n\n1. All brain tumors with a favorable prognosis (median survival \\> 10 year)\n2. Age ≥ 18 years\n3. ECOG performance status 0 - 1 \u002F Karnofsky performance status 80 - 100\n4. No - minimal neurocognitive impairment\n5. Dosimetrical gain of protontherapy relative to photontherapy (≥5% on supratentorial brain dose or hippocampi)\n6. Informed consent\n\nExclusion Criteria:\n\n1. Not eligible for chemotherapy\n2. Eligible for stereotactic radiotherapy",{"count":165,"type":19},1500,"5 Years","The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of secondary tumours. The Netherlands has spearheaded the development of the model-based approach (MBA) for the selection of patients for proton therapy when applied to prevent radiation-induced complications. In MBA, a pre-treatment in-silico planning study is done, comparing proton and photon treatment plans in each individual patient, to determine (1) whether there is a significant difference in dose in the relevant organs at risk (ΔDose), and (2) whether this dose difference translates into an expected clinical benefit in terms of NormalTissue Complication Probabilities (ΔNTCP). To translate ΔDose into ΔNTCP, NTCP-models are used, which are prediction models describing the relation between dose parameters and the likelihood of radiation-induced complications. The Dutch Society for Radiotherapy and Oncology (NVRO) setup the selection criteria for proton therapy in 2015, taking into account toxicity and NTCP. However, NTCP-models can be affected by changes in the irradiation technique. Therefore, it is paramount to continuously update and validate these NTCP-models in subsequent patient cohorts treated with new techniques. In ProTRAIT, a Findable, Accessible, Interoperable and Reusable (FAIR)data infrastructure for both clinical and 3D image and 3D dose information has been developed and deployed for proton therapy in the Netherlands. It allows for a prospective, standardized, multi-centric data from all Dutch proton and a representative group of photon therapy patients.",[169,170,171,172,173,174,175,26,176,177,178,179],"Astrocytoma","Ependymoma","Ganglioglioma","Oligodendroglioma","Optic Nerve Glioma","Meningioma","Nerve Sheath Neoplasms","Craniopharyngioma","Hemangiopericytoma","Germinoma","Neurilemmoma","2024-11-25",{"date":182,"type":34},"2024-11-26",{"date":184,"type":34},"2018-01-01",{"date":186,"type":19},"2035-01-01",{"name":188,"class":41},"Maastricht Radiation Oncology",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":20,"phases":199,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":4},"100555737","texture-and-colour-enhancement-imaging-in-improving-detection-and-miss-rate-of-premalignant-lesions-100555737","NCT06515977","Texture and Colour Enhancement Imaging in Improving Detection and Miss Rate of Premalignant Lesions","Impact of Texture and Color Enhancement Imaging on Detection and Miss Rate of Premalignant Lesions: A Multicentre, Randomized, Tandem Trial","Inclusion Criteria:\n\npatients aged 45-85 years and scheduled for screening colonoscopy who provided written informed consent\n\nExclusion Criteria:\n\nSurveillance, diagnostic or therapeutic colonoscopy\n\nPatients with an already known or suspected colorectal tumour\n\nPatients with alarming symptoms and signs, including haematochezia, melena, weight loss or anaemia without specific causes, an abdominal mass and positive digital rectal examination\n\nPregnant or lactating women\n\nPatients with gastrointestinal tract obstruction\n\nPatients with inflammatory bowel diseases, hereditary CRC syndromes or serrated polyposis syndrome\n\nPatients with abnormal blood coagulation or taking antiplatelets or anticoagulants within 7 days before colonoscopy\n\nPatients with failed cecal intubation\n\nPatients with poor bowel preparation quality that necessitated a second bowel preparation\n\nPatients with a history of colonic resection","85 Years",{"count":198,"type":19},2964,[56],"Texture and Color Enhancement Imaging (TXI) is a newly developed image-enhancing endoscopy technology that has show potential in improving detection of colorectal lesions. This multicenter, randomized, tandem trial is aimed at evaluating whether TXI is superior to WLI endoscopy in terms of diagnosis of premalignant lesions.",[26,202],"Sessile Serrated Adenoma",[204,205,206,207,208,209],"texture and color enhancement imaging","colonoscopy","adenoma detection rate","sessile serrated lesion detection rate","adenoma miss rate","sessile serrated lesion miss rate","2024-07-17",{"date":212,"type":34},"2024-07-23",{"date":214,"type":19},"2024-08-01",{"date":125,"type":19},{"name":217,"class":41},"Changhai Hospital",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":51,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},"100533038","multi-omics-study-for-early-detection-of-colorectal-cancer-moed-crc-100533038","NCT06220617","Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)","Multi-omics Study for Early Detection of Colorectal Cancer Based on Liquid Biopsy Technology","Inclusion Criteria for Case Arm:\n\n1. Aged over 18 years.\n2. Participants confirmed with colorectal adenocarcinoma or advanced adenoma through colonoscopy and pathological examination.\n3. Provision of informed consent prior to any study specific procedures, sampling, and analyses.\n\nInclusion Criteria for Control Arm:\n\n1. Individuals of \"General risk arm\" should meet all the following criteria:\n\n   1. No history of colorectal adenomas or sessile serrated polyps.\n   2. No history of inflammatory bowel disease (8-10 years ).\n   3. No family history (first-degree relatives) of colorectal cancer.\n2. Individuals of \"High-risk arm\" should meet at least one of the following criteria:\n\n   1. Asia-Pacific Colorectal Screening (APC) score ≥ 3.\n   2. Family history (first-degree relatives) of colorectal cancer.\n   3. History of positive fecal occult blood test.\n   4. Any 2 of the following: chronic diarrhea, chronic constipation, mucous bloody stools, history of psychological stimulation, history of chronic appendicitis or appendectomy, history of chronic biliary disease or cholecystectomy.\n   5. Individuals with inflammatory bowel disease.\n3. All participants must be confirmed not to have colorectal malignancy or advanced adenomas through colonoscopy.\n4. Provision of informed consent prior to any study specific procedures, sampling, and analyses.\n\nExclusion Criteria:\n\n1. History of other malignant tumors (excluding non-melanoma skin cancer).\n2. Prior or related treatments previously (including colorectal cancer or advanced adenoma surgery, endoscopic treatment, chemotherapy, targeted therapy, immunotherapy, radiation, neoadjuvant therapy, etc.).\n3. Patients with hereditary colorectal diseases (including Lynch syndrome, familial CRC type X (FCCX), familial adenomatous polyposis (FAP), MUTHY-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), serrated polyposis syndrome (SPS), etc.).\n4. Usage of anti-tumor drugs such as methotrexate, cyclophosphamide, mercaptopurine, and bendamustine for other diseases within 30 days before blood collection.\n5. Prior blood transfusion (including blood components) within the past 2 weeks.\n6. Prior organ transplantation, bone marrow transplantation, or stem cell transplantation.\n7. Pregnancy women.\n8. Prior or current anti-infection treatment within 14 days before blood collection.\n9. Inability to comply with study procedures such as blood collection and related examinations.\n10. Deemed unsuitable for participation in the clinical trial by the investigator.",{"count":226,"type":19},3600,"The primary objective of the study is to screen multi-omics markers in blood samples and construct a prediction model for CRC based on liquid biopsy, and we will further optimize the prediction model by validating its clinical performance externally.",[28,229,26,230],"Adenomatous Polyps","Advanced Adenoma",[28,59,229,26,232],"Advanced adenoma","2024-01-28",{"date":235,"type":34},"2024-01-30",{"date":237,"type":34},"2024-01-11",{"date":239,"type":19},"2027-06-30",{"name":75,"class":41},6]